|Thursday, 11 January 2018, 15:00 HKT/SGT|
Paris, France and Cambridge, Massachusetts, USA, Jan 11, 2018 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy.
The collaboration with Providence Cancer Institute, located at the Robert W. Franz Cancer Center in Portland, Ore., one of the world's leading oncological research centers, will provide essential preclinical data on the ability of NBTXR3 activated by radiotherapy to induce an antitumoral immune response. This is an in-depth study into the early immunologic mechanisms, triggered by nanoparticles activated by radiotherapy compared to radiotherapy alone, and their impact on tumor control, survival and metastasis spreading.
Marka R. Crittenden, M.D., Ph.D., radiation oncologist and director of Translational Radiation Research at the Robert W. Franz Cancer Center will lead the program. "Promising pre-clinical data suggests that nanoparticles combined with radiotherapy enhance tumor-specific immune responses and lead to an abscopal response, priming a patient's immune system to attack cancer cells outside of the radiotherapy target area," she said. "Furthermore, we are absolutely delighted to partner with Nanobiotix to advance our research on this phenomenon and the role NBTXR3 can play in immuno-oncology."
The collaboration between Providence and Nanobiotix will take place over the course of one year, and will evaluate the use of NBTXR3 activated by radiotherapy in pancreatic cancer models (in vitro and in vivo). Pancreatic cancer is a disease with a substantial unmet medical need, poor response to standard of care and is the third leading cause of cancer mortality in both men and women in the United State. Pancreatic cancers have a non-immunogenic tumor microenvironnement, known as "cold tumors", and often have a poor response rate to immunotherapies.
The results of this joint program will enable the potential to explore future use of NBTXR3 in immuno-oncology as well as its potential to control metastatic disease.
In parallel, the Company has received the approval of its Investigational New Drug (IND) and will launch its first clinical trial combining NBTXR3 with immune checkpoint inhibitors in the U.S. with a multi-arm trial targeting a sub-population of advanced lung cancer patients and head and neck cancer patients. Nanobiotix's immuno-oncology combination program opens the door to new developments, potential new indications and important value creation opportunities.
About Providence Cancer Institute
Providence Cancer Institute, a part of Providence Health & Services, offers the latest in cancer services, including diagnostic, treatment, prevention, education, support and internationally-renowned research. Located within the Robert W. Franz Cancer Center in Portland, Ore., Providence Cancer Institute is home to the Earle A. Chiles Research Institute, a world-class research facility for cancer immunotherapy, a specialized field of study focused on triggering the immune system to fight cancer. Visit www.providenceoregon.org/cancer to learn more.
NBTXR3 is an injectable aqueous suspension of hafnium oxide nanoparticles designed as an innovative therapeutic agent for the treatment of solid tumors, currently in clinical development by Nanobiotix.
Once injected intratumorally, NBTXR3 can deposit high energy within tumors only when activated by an ionizing radiation source, notably radiotherapy. Upon activation, the high energy radiation is physically designed to kill the tumor cells by triggering DNA damage and cell destruction and improve clinical outcomes.
Promising results indicate that NBTXR3 activity could be applicable across solid tumors triggering immunogenic cell death, leading to an immune response, reinforcing a local and potentially systemic effect, and contributing to transform "cold" tumors into "hot" tumors. NBTXR3's major characteristics are represented by a high degree of biocompatibility, one single administration before and during the whole therapy and the ability to fit into current standards of radiotherapy care.
NBTXR3 entered clinical development in 2011 in a Phase I/II with patients suffering from advanced soft tissue sarcoma of the extremities and is currently in the final stages of its subsequent phase II/III. In parallel, it is currently being tested in numerous Phase I/II clinical trials with patients suffering from locally advanced squamous cell carcinoma of the oral cavity or oropharynx (head and neck), liver cancer (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region.
The Company started a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company's Headquarters is based in Paris, France, with a U.S. affiliate in Cambridge, MA.
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
email@example.com / firstname.lastname@example.org
Director, Investor Relations
+1 (646) 241-4400
email@example.com / firstname.lastname@example.org
France - Springbok Consultants
+33 (0)6 71 58 00 34
United States - RooneyPartners
+1 (212) 223-4017
Providence Cancer Institute
Jean Powell Marks
+1 (503) 215-6433
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.
Jan 11, 2018 15:00 HKT/SGT
Topic: Research and development
Sectors: Science & Research, BioTech, HealthCare
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Jan 22, 2018 15:00 HKT/SGT|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting|
|Dec 26, 2017 15:50 HKT/SGT|
Nanobiotix: 2017 review and 2018 expected milestones|
|Dec 26, 2017 15:15 HKT/SGT|
FDA approves Nanobiotix's first Immuno-Oncology trial|
|Nov 13, 2017 15:00 HKT/SGT|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting|
|Nov 10, 2017 08:30 HKT/SGT|
Nanobiotix provides update on the global development of its lead product NBTXR3|
|Oct 23, 2017 14:00 HKT/SGT|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma|
|Sept 29, 2017 08:00 HKT/SGT|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.|
|Sept 1, 2017 01:30 HKT/SGT|
Nanobiotix half year results for the six months ended 30 June 2017|
|June 16, 2017 06:00 HKT/SGT|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop|
|June 6, 2017 00:00 HKT/SGT|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting|
|More news >>|